Modulation of Therapeutic Response
Modulation of Therapeutic Response
批准号:
10926564
负责人:
James Mitchell
金额:
$175.3万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressAttentionBlood VesselsBlood flowCDK4 geneCancer cell lineClinicalClinical TrialsCombined Modality TherapyDataElectron Spin Resonance SpectroscopyEvaluationGoalsGrowthHIF1A geneHeat-Shock Proteins 90HumanHypoxiaImageIn VitroIonizing radiationKRAS2 geneLactate DehydrogenaseMagnetic Resonance ImagingMalignant Epithelial CellMeasurementMetabolicMetabolismModificationMolecularMolecular TargetMutationNormal tissue morphologyOxidative PhosphorylationOxygenOxygen ConsumptionPancreatic carcinomaPharmaceutical PreparationsPharmacotherapyPhysiologyProcessProductionPyruvateRadiationRadiation Induced DNA DamageRadiation OncologyRadiation ToleranceRadiation induced damageRadiation therapyRadiation-Protective AgentsRadiation-Sensitizing AgentsRadiosensitizationResearchResearch DesignStromal Cell-Derived Factor 1TherapeuticTissuesTranslatingTumor TissueXenograft procedurecancer cellcancer clinical trialcancer therapychemotherapyimaging approachimprovedin vivoinhibitorinterestlung cancer cellmetabolic imagingmolecular imagingnon-invasive monitornovelpancreatic cancer cellspre-clinicalpre-clinical researchpreclinical studyradiation effectradiation responseradioresistantrepairedresponsetargeted agenttreatment responsetumortumor growthtumor metabolismtumor microenvironmentvasculogenesis
中文摘要
为了改善癌症治疗,相当多的注意力已经放在辐射损伤的修饰上。正在研究各种化疗和/或分子靶向药物与放射的相互作用,以确定是否可以使肿瘤对放射治疗更敏感或使正常组织对放射治疗更耐受。中心目标是确定将导致净治疗收益的方法,从而改善癌症的放射治疗。该项目的一个目标是定义和更好地了解肿瘤生理学的这些方面,包括细胞和分子过程以及肿瘤微环境对治疗反应的影响。增强肿瘤对辐射的响应而不增强给定治疗区域内的正常组织的能力是期望的。CDK 4/6抑制剂(abemaciclib)和HSP 90抑制剂(AT 13387)均被证明是人类癌细胞的有效辐射增敏剂。此外,这两种药物都抑制了肿瘤血管发生,这是一个在辐射后用血管重新供应肿瘤导致肿瘤再生长的过程。我们正在确定血管生成抑制的机制,我们发现这两种药物都抑制HIF-1 α和SDF-1。我们目前正在评估几种成像方法,以确定药物治疗结合放射治疗后的血流量。血管生成的抑制应导致治疗后肿瘤中血流受损。我们的初步数据表明,治疗后的肿瘤血流量确实减少了。我们继续评估一些代谢抑制剂作为辐射改性剂的工作假设下,抑制代谢(例如,减少ATP的生产)将减少辐射诱导的DNA损伤的修复。体外研究表明,一种新的乳酸脱氢酶抑制剂(LDHAi)可增强人胰腺癌细胞的放射敏感性。用这种药剂进行的初步异种移植研究表明,单独使用药物可以延缓肿瘤生长,但不能增强放射反应。我们还发现氧化磷酸化抑制剂在体外放射增敏作用很小,在体内放射增敏作用不明显。OxPhos抑制剂明显导致肿瘤中的氧消耗减少,从而降低肿瘤中的缺氧分数,并因此降低辐射敏化。在过去的一年中,我们使用在KRAS中具有特定突变(G12 C)的胰腺癌和肺癌细胞系,对两种KRAS突变抑制剂(AMG 510,MRTD 849)进行了扩展研究。这两种药物也显示出体外和体内放射增敏作用。我们还使用13 C-丙酮酸盐MRI对肿瘤代谢进行非侵入性监测,以评估肿瘤代谢的变化,以及针对肿瘤血流和缺氧状态的MRI研究。我们最近获得了三种不同的G12 C突变抑制剂进行评估。这些临床前研究将提供必要的信息,以考虑在肿瘤放射增敏的临床人体试验中使用这些药物。总的来说,我们已经确定了许多临床前方法,以启动人类放射肿瘤学临床试验,以调节辐射对肿瘤的影响。
英文摘要
In the interest of improving cancer treatment, considerable attention has been placed on the modification of radiation damage. The interaction of a variety of chemotherapy and/or molecularly targeted agents with radiation is under study to determine if tumors can be made more sensitive or normal tissues more resistant to radiation treatment. The central aim is to identify approaches that will result in a net therapeutic gain, thus improving cancer treatment with radiation. One goal of the project is to define and better understand those aspects of tumor physiology, including cellular and molecular processes and the influence of the tumor microenvironment on treatment response. The ability to enhance the response of the tumor to radiation, without enhancing normal tissue within a given treatment field is desirable. Both a CDK4/6 inhibitor (abemaciclib) and a HSP90 inhibitor (AT13387) was was shown to be potent radiation sensitizers of human cancer cells. Further, both agents inhibited tumor vasculogenesis, which is a process following radiation that resupplies the tumor with blood vessels resulting in tumor regrowth. We are in the process of determining the mechanism of vasculogenesis inhibition which we have found that both agents that inhibit HIF-1alpha and SDF-1. We are currently using evaluating several imaging approaches to determine blood flow following drug treatment combined with radiation. Inhibition of vasculogenesis should result in compromised blood flow in the tumor following treatment. Our preliminary data suggest that indeed blood flow in the treated tumor is reduced. We continue to evaluate a number of metabolic inhibitors as radiation modifiers under the working hypothesis that inhibition of metabolism (for example, decreased ATP production) will diminish the repair of radiation-induced DNA damage. In vitro studies have shown that a novel lactate dehydrogenase inhibitor (LDHAi) enhances the radiosensitivity of human pancreatic carcinoma cells. Preliminary xenograft studies with this agent have shown tumor growth delay with drug alone, but no enhancement of the radiation response. We have also found that an inhibitor of oxidative phosphorylation has little effects of in vitro radiosensitization, not significant radiosensitization in vivo. The OxPhos inhibitor clearly results in less oxygen consumption in tumors thereby decreasing the hypoxic fraction in tumors and hence radiation sensitization. We have expanded studies this past year on two KRAS mutation inhibitors (AMG510, MRTD849) using pancreatic and lung cancer cell lines which have the specific mutations (G12C) in KRAS. These two agents also show in vitro and in vivo radiosensitization. We are also conducting non-invasive monitoring of tumor metabolism using 13C-pyruvate MRI to assess changes in tumor metabolism as well as MRI studies that address tumor blood flow and hypoxia status. We have recently acquired three different inhibitors of G12C mutations for evaluation. These pre-clinical studies will provide the necessary information to consider these agents in a clinical human trial for tumor radiosensitization. Collectively, we have identified a number of pre-clinical approaches to initiate human radiation oncology clinical trials for modulation of radiation effects on tumors.
期刊论文(46)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1186/1748-717x-5-8
发表时间:
2010-02-03
期刊:
Radiation oncology (London, England)
影响因子:
--
作者:
[Soule BP, Simone NL, DeGraff WG, Choudhuri R, Cook JA, Mitchell JB]
通讯作者:
Mitchell JB
DOI:
10.1016/j.freeradbiomed.2011.05.019
发表时间:
2011-08-01
期刊:
FREE RADICAL BIOLOGY AND MEDICINE
影响因子:
7.4
作者:
[Davis, Ryan M., Sowers, Anastasia L., DeGraff, William, Bernardo, Marcelino, Thetford, Angela, Krishna, Murali C., Mitchell, James B.]
通讯作者:
Mitchell, James B.
DOI:
10.1158/1078-0432.ccr-11-0358
发表时间:
2011-08-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[Urick ME, Chung EJ, Shield WP 3rd, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J, Citrin DE]
通讯作者:
Citrin DE
DOI:
10.1038/bmt.2009.121
发表时间:
2010-01
期刊:
BONE MARROW TRANSPLANTATION
影响因子:
4.8
作者:
[Singh, A. K., Chen, J., Calado, R., Sowers, A., Mitchell, J. B., Barrett, A. J.]
通讯作者:
Barrett, A. J.
DOI:
10.1371/journal.pone.0024429
发表时间:
2011
期刊:
PloS one
影响因子:
3.7
作者:
[Saleh AD, Savage JE, Cao L, Soule BP, Ly D, DeGraff W, Harris CC, Mitchell JB, Simone NL]
通讯作者:
Simone NL
共 31 条
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10487178
-
项目类别:
-
资助金额:$23.68万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8554011
-
项目类别:
-
资助金额:$66.27万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8350044
-
项目类别:
-
资助金额:$70.69万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:9154244
-
项目类别:
-
资助金额:$67.78万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:10702438
-
项目类别:
-
资助金额:$114.64万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:8349242
-
项目类别:
-
资助金额:$32.13万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:8349161
-
项目类别:
-
资助金额:$55.7万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:8938387
-
项目类别:
-
资助金额:$63.42万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10262691
-
项目类别:
-
资助金额:$138.88万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10262693
-
项目类别:
-
资助金额:$27.78万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8158259
-
项目类别:
-
资助金额:$64.92万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:9153721
-
项目类别:
-
资助金额:$65.79万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:8937900
-
项目类别:
-
资助金额:$63.42万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10926566
-
项目类别:
-
资助金额:$58.43万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10487176
-
项目类别:
-
资助金额:$118.41万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Imaging Probe Development Center
-
批准号:8746870
-
项目类别:
-
资助金额:$370.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:8552827
-
项目类别:
-
资助金额:$30.12万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:7592935
-
项目类别:
-
资助金额:$31.76万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10702987
-
项目类别:
-
资助金额:$143.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:8763677
-
项目类别:
-
资助金额:$54.34万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位:
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:82202156
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位: